CJC-1295 and Ipamorelin: What the Evidence Actually Shows

Compounding sellers and research-chemical vendors rarely list CJC-1295 and ipamorelin as separate products — search either name and you'll usually land on a combined SKU, sold and dosed as one pairing. This site's own provider research found the same pattern directly: the one non-boarded seller in this site's catalog research that carries either compound lists it as a single product, "CJC-1295 / Ipamorelin," one price, one syringe. This article is the standalone evidence review for that pairing — not a comparison against sermorelin, which our three-way comparison and our two-way ipamorelin-vs-sermorelin piece already cover in depth. This one asks a narrower question: what does each compound's own trial evidence actually show, and does anything support combining them the way they're sold?

Two different mechanisms, sold as one product

CJC-1295 is a GHRH-receptor agonist — an engineered, longer-acting version of growth-hormone-releasing hormone, the signal the hypothalamus itself uses to trigger pituitary GH release. Ipamorelin is a ghrelin-receptor agonist — a small pentapeptide activating an entirely different receptor (GHS-R1a), the same one ghrelin itself binds. They don't compete for the same target; they act on two separate levers of the same downstream system, which is the entire mechanistic case for selling them together. Ipamorelin's own discovery paper describes it as the first compound in its class shown to be selective — in pigs, doses more than 200-fold above the GH-releasing threshold didn't raise cortisol or ACTH the way older ghrelin-receptor compounds did in the same experiments³. That selectivity finding is real, and it's also worth naming precisely: it comes from anesthetized rats and conscious pigs, not a controlled human outcome trial.

CJC-1295 is not one molecule — and that distinction matters here specifically

"CJC-1295" gets used as a single name for two chemically different products, and the difference isn't cosmetic. The molecule the compound's own 2005 discovery paper actually describes is a form of hGRF(1-29) modified with a reactive maleimide group specifically so it binds circulating serum albumin — the paper's own language is "identification of CJC-1295 as a long-lasting GRF analog," present in a rat's plasma "beyond 72 h" because of that albumin conjugation¹. That albumin-binding technology has a name in the literature: DAC, for drug affinity complex. The version sold commercially without that modification — "CJC-1295 without DAC," also marketed as "Mod GRF 1-29" — removes exactly the feature that made the original molecule long-acting in the first place.

A 2026 narrative review that specifically set out to separate peer-reviewed evidence from online self-administration protocols states this distinction directly and, more importantly, reports the trial record for each version separately⁶. CJC-1295 with DAC has real human data: the same placebo-controlled, ascending-dose trial both this site's comparison articles already cite, run across two studies (28 and 49 days) in adults aged 21-61, showing dose-dependent GH increases of 2- to 10-fold sustained for six or more days, and IGF-1 increases of 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days and no serious adverse reactions². CJC-1295 without DAC has none of that. The 2026 review's own words: it "remains essentially uncharacterised in the peer-reviewed human literature. To date, no controlled clinical studies have directly evaluated this compound in humans"⁶. Its own evidence-tier table places CJC-1295-with-DAC in tier B (real phase I/II human data, no controlled efficacy trial) and CJC-1295-without-DAC in tier D — the review's lowest category, reserved for compounds "supported only by preclinical extrapolation and grey-literature user narratives," alongside PEG-MGF and IGF-1 LR3⁶.

Here's why that split is the actual point of this article rather than a footnote: the same 2026 review states that when ipamorelin gets combined with CJC-1295 in off-label fitness use, it is "typically the non-DAC form"⁶. That means the CJC-1295/ipamorelin pairing most commonly sold isn't built on the one CJC-1295 variant with real placebo-controlled biomarker data behind it — it's built on the one with zero peer-reviewed human studies of any kind.

Ipamorelin: a confirmed mechanism, and one outcome trial that missed

Ipamorelin's human evidence is real but narrow. A 1999 dose-escalation pharmacokinetic study in eight healthy male volunteers per dose level confirmed the mechanism translates to people: intravenous ipamorelin triggers a single, time-limited pulse of GH release, peaking around 40 minutes after infusion and clearing with a roughly 2-hour half-life⁴. That's a genuine, useful confirmation that the compound does what it's supposed to do acutely in humans — and it's the extent of what that study measured.

The one randomized, placebo-controlled trial of ipamorelin that tested an actual clinical outcome has nothing to do with muscle, fat, or aging. It's a 2014 multicenter phase 2 trial of intravenous ipamorelin for postoperative ileus — sluggish bowel function after abdominal surgery — in 114 hospitalized surgical patients, based on ghrelin receptors' separate role in gut motility. The primary endpoint, time to tolerating a solid meal, ran 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that did not reach statistical significance (p = 0.15)⁵. That is the entire published record of a controlled ipamorelin outcome trial in humans, for an indication unrelated to why it's marketed today, and it missed. Nothing resembling a controlled trial of ipamorelin for body composition, fat loss, sleep, or anti-aging in adults exists in the published literature.

Why they're sold together — and why no trial has tested that specific claim

The pitch behind combining a GHRH analog with a ghrelin-receptor agonist is coherent on paper: they act on two different levers of the same pituitary output, so stacking them is marketed as producing a bigger, more sustained GH pulse than either alone. The 2026 review above states this rationale plainly, in the same sentence that flags the problem with it: ipamorelin combined with CJC-1295 is intended "to amplify GH release through complementary stimulation of the GH axis. However, this practice is largely driven by anecdotal rationale, and controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains li[mited]"⁶. A direct PubMed search for both compound names together, run for this article, returns nine results — none of them a controlled trial of the combination. What comes back instead is a set of 2026 narrative reviews (this section's own source among them) surveying the broader performance-enhancing-peptide landscape, plus one 2013 doping-detection paper using both as reference standards in horse plasma. No study — in any species, at any dose — has tested CJC-1295 and ipamorelin given together against either compound alone or against placebo. The mechanistic argument for the pairing is real; the trial that would confirm it produces anything more than either compound alone does not exist.

The regulatory picture — and a correction this article found while checking it live

Neither compound has ever had an FDA-approved drug product. A direct DailyMed search — the National Library of Medicine's own archive of FDA-approved labeling — returns zero results for both "CJC-1295" and "ipamorelin," reconfirmed live for this article⁹¹⁰. FDA's Pharmacy Compounding Advisory Committee formally reviewed both: at its December 4, 2024 meeting, FDA proposed that none of the five nominated CJC-1295-related forms — free base, acetate, DAC free base, DAC acetate, and DAC trifluoroacetate — be added to the 503A compounding bulks list⁷; at its October 29, 2024 meeting, FDA reached the same conclusion for ipamorelin, stating directly that there are "no data to support the effectiveness of ipamorelin... for the proposed [subcutaneous] route of administration" for either growth-hormone deficiency or postoperative ileus⁸. FDA's current 503A Bulks List — updated May 14, 2026, fetched and read in full for this article — confirms neither compound sits in any of the three nomination categories today.

One specific claim was checked directly rather than repeated: the same 2026 review cited above for the DAC/no-DAC distinction also states that FDA lists CJC-1295 in "Category 2 of Bulk Drug Substances List... due to vasodilatatory reactions and tachycardia reports." Reading FDA's actual current document rather than trusting that citation, Category 2 contains exactly six substances — Cesium Chloride, Domperidone, Germanium Sesquioxide, Ibutamoren Mesylate, Kisspeptin-10, and Quinacrine Hydrochloride (intrauterine use only) — and CJC-1295 is not one of them. The compound actually flagged there for a tachycardia-type safety signal is ibutamoren mesylate, the salt form of MK-677 — a different, non-peptide, orally active ghrelin-receptor agonist sometimes sold alongside these two peptides, covered in full in this site's own MK-677 vs. sermorelin comparison, including the cardiac trial that was stopped early over that exact signal. Whether the review's own source conflated the two compounds or referenced an FDA action since superseded isn't something this article can resolve — what it can do is report what FDA's own current, directly-read document actually says, which is that neither CJC-1295 nor ipamorelin is on the agency's active safety-concern list, under either category, as of the May 2026 update.

The safety signal that exists — and it's thin for both

FDA's Adverse Event Reporting System (FAERS), counted live for this article, names CJC-1295 in exactly 4 reports total — the smallest count of any compound this corpus has checked — spanning a scattered mix of reactions (acute kidney injury, blood glucose increased, drug hypersensitivity, heart rate increased, myocardial infarction, injection-site abscess, and several product-quality/dispensing-error terms), each appearing once. Ipamorelin's count is 11 reports total, the same figure this site's own ipamorelin-vs-sermorelin comparison already established, reconfirmed fresh for this article — and its single most frequent reaction, "recalled product administered" (4 of the 11), is a supply-chain finding, not a pharmacological one. Read both counts in both directions, honestly: neither shows an alarming pattern, and neither is remotely large enough to compute an incidence rate from. Spontaneous-report databases undercount compounded-drug exposure structurally, since outsourcing pharmacies and prescribers aren't required to report the way an approved drug's manufacturer is. Four and eleven reports are evidence of thin reporting, not evidence of safety.

What this means if you're considering this pairing

None of the 31 providers this site's own reviews cover sell CJC-1295 or ipamorelin as a primary, boarded product — this site's own identity-layer research (the same data that builds its three provider boards) confirms neither compound is tagged to a single reviewed seller as a standalone offering. That's a real, checked fact, not a hedge, and it means this article can't point you toward a board comparison the way its sermorelin-focused siblings do. If the prescribable, board-reviewed GH-axis option is actually what you're after, our sermorelin provider rankings are this site's only board covering that category — sermorelin isn't the same compound and isn't sold as a pairing, but it's the one GHRH-class agonist this site has actually reviewed sellers for. This site's ipamorelin reconstitution calculator does the vial-to-syringe arithmetic for ipamorelin specifically; there's no dedicated CJC-1295 calculator on this site today, an honest gap rather than an oversight, since neither CJC-1295 variant has an FDA-set vial strength for a calculator to check anything against.

Put together: CJC-1295 with DAC has genuinely strong biomarker evidence in healthy adults, over weeks, for raising and sustaining GH and IGF-1 — evidence about hormone levels, not about body composition, strength, or longevity outcomes, which that trial didn't test. CJC-1295 without DAC — the form most commonly paired with ipamorelin in the products actually sold — has no peer-reviewed human data of any kind. Ipamorelin has a confirmed acute mechanism in eight healthy volunteers and exactly one placebo-controlled outcome trial, for an unrelated surgical indication, that missed its endpoint. And the specific claim implied by selling them together — that the combination does more than either compound alone — has never been tested, in any study, at any dose. The rationale for pairing them is a real mechanistic argument about two different receptors on the same axis; it is not, today, a demonstrated result.